Luye Pharma Group announced today that a Phase III clinical trial of its innovative formulation for the treatment of prostate cancer, Goserelin Acetate Extended-release Microspheres for Injection (LY0...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
The global COVID-19 pandemic poses a serious threat to physical health and has wide-ranging implications for mental health worldwide. At the third Asia Pacific Psychiatry Symposium, held online on Jun...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody Therapeutics...
Dear Business Partners & Customers,To accommodate our growing business, Luye Life Sciences Group Shanghai Office will be relocated from Building 12, Shanghai Business Park III, No.1036 Tianlin Roa...
Luye Pharma Group announced that the marketing authorization application for the company’s in-house developed Class 1 new drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has be...
Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD). With the end of proc...
Luye Pharma Group announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection), developed by the Group’s holding subsidiary Boan Biotech, has received marketing authorization from Ch...
GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled‘Design and synthesis of novel GalNAc linker moie...
Luye Pharma Group announced that a research paper on LY-CovMab, an innovative antibody developed by Boan Biotech, a holding subsidiary of the Group, has been published in Communications Biology, a sub...
TOP